|
Entant Pharmaceuticals, Inc. (ENTA) Évaluation DCF
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Enanta Pharmaceuticals, Inc. (ENTA) Bundle
Découvrez la vraie valeur d'Eanta Pharmaceuticals, Inc. (ENTA) avec notre calculatrice DCF de qualité professionnelle! Ajustez les hypothèses clés, explorez divers scénarios et évaluez comment les différents changements affectent l'évaluation d'Eanta Pharmaceuticals, Inc. (ENTA) - le tout dans un modèle EXCEL complet.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122.5 | 97.1 | 86.2 | 79.2 | 67.6 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Revenue Growth, % | 0 | -20.74 | -11.24 | -8.07 | -14.61 | -13.67 | -13.67 | -13.67 | -13.67 | -13.67 |
| EBITDA | -38.0 | -104.2 | -119.2 | -123.5 | -104.5 | -50.3 | -43.5 | -37.5 | -32.4 | -28.0 |
| EBITDA, % | -31.02 | -107.39 | -138.36 | -155.9 | -154.52 | -86.2 | -86.2 | -86.2 | -86.2 | -86.2 |
| Depreciation | 3.6 | 3.3 | 3.0 | 2.4 | 2.3 | 1.9 | 1.6 | 1.4 | 1.2 | 1.1 |
| Depreciation, % | 2.98 | 3.43 | 3.45 | 2.99 | 3.45 | 3.26 | 3.26 | 3.26 | 3.26 | 3.26 |
| EBIT | -41.6 | -107.6 | -122.2 | -125.8 | -106.8 | -50.7 | -43.8 | -37.8 | -32.6 | -28.2 |
| EBIT, % | -34 | -110.82 | -141.82 | -158.89 | -157.98 | -86.8 | -86.8 | -86.8 | -86.8 | -86.8 |
| Total Cash | 386.6 | 244.0 | 249.2 | 369.9 | 248.2 | 58.4 | 50.4 | 43.5 | 37.6 | 32.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 23.5 | 60.8 | 49.0 | 39.6 | 6.6 | 23.2 | 20.0 | 17.3 | 14.9 | 12.9 |
| Account Receivables, % | 19.18 | 62.66 | 56.91 | 50.02 | 9.83 | 39.72 | 39.72 | 39.72 | 39.72 | 39.72 |
| Inventories | .0 | -37.3 | .0 | .0 | .0 | -4.5 | -3.9 | -3.3 | -2.9 | -2.5 |
| Inventories, % | 0 | -38.38 | 0 | 0 | 0 | -7.68 | -7.68 | -7.68 | -7.68 | -7.68 |
| Accounts Payable | 5.7 | 9.5 | 6.0 | 4.1 | 8.0 | 4.5 | 3.9 | 3.3 | 2.9 | 2.5 |
| Accounts Payable, % | 4.68 | 9.83 | 6.96 | 5.17 | 11.83 | 7.7 | 7.7 | 7.7 | 7.7 | 7.7 |
| Capital Expenditure | -1.4 | -.8 | -2.1 | -9.1 | -17.9 | -5.0 | -4.3 | -3.7 | -3.2 | -2.8 |
| Capital Expenditure, % | -1.18 | -0.77261 | -2.47 | -11.44 | -26.54 | -8.48 | -8.48 | -8.48 | -8.48 | -8.48 |
| Tax Rate, % | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 | 1.48 |
| EBITAT | -43.0 | -79.0 | -121.8 | -128.6 | -105.3 | -47.8 | -41.3 | -35.6 | -30.8 | -26.6 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -58.6 | -72.7 | -149.9 | -127.7 | -84.0 | -66.4 | -42.0 | -36.2 | -31.3 | -27.0 |
| WACC, % | 9.89 | 8.57 | 9.87 | 9.89 | 9.82 | 9.61 | 9.61 | 9.61 | 9.61 | 9.61 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -161.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -28 | |||||||||
| Terminal Value | -362 | |||||||||
| Present Terminal Value | -229 | |||||||||
| Enterprise Value | -391 | |||||||||
| Net Debt | 18 | |||||||||
| Equity Value | -409 | |||||||||
| Diluted Shares Outstanding, MM | 21 | |||||||||
| Equity Value Per Share | -19.32 |
What You Will Get
- Editable Forecast Inputs: Effortlessly modify key assumptions (growth %, margins, WACC) to explore various scenarios.
- Real-World Data: Enanta Pharmaceuticals, Inc.'s (ENTA) financial data pre-loaded to kickstart your analysis.
- Automatic DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value for you automatically.
- Customizable and Professional: A sleek Excel model tailored to fit your valuation requirements.
- Built for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and enhancing efficiency.
Key Features
- Comprehensive DCF Calculator: Offers detailed unlevered and levered DCF valuation models tailored for Enanta Pharmaceuticals, Inc. (ENTA).
- WACC Calculator: Features a pre-built Weighted Average Cost of Capital sheet with adjustable inputs specific to the pharmaceutical sector.
- Customizable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit Enanta's financial outlook.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios relevant to Enanta Pharmaceuticals, Inc. (ENTA).
- Visual Dashboard and Charts: Present visual summaries of key valuation metrics for straightforward analysis and decision-making.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Enanta Pharmaceuticals' pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and leverage the results for your investment strategies.
Why Choose This Calculator for Enanta Pharmaceuticals, Inc. (ENTA)?
- Accurate Data: Utilize real Enanta Pharmaceuticals financials for dependable valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the hassle of starting from the ground up.
- Professional-Grade Tool: Tailored for investors, analysts, and consultants in the pharmaceutical sector.
- User-Friendly: Easy-to-navigate design and step-by-step guidance cater to users of all experience levels.
Who Should Use This Product?
- Investors: Assess the fair value of Enanta Pharmaceuticals (ENTA) to inform your investment choices.
- CFOs: Utilize a high-quality DCF model for accurate financial reporting and analysis related to Enanta Pharmaceuticals (ENTA).
- Consultants: Efficiently modify the template for client valuation reports involving Enanta Pharmaceuticals (ENTA).
- Entrepreneurs: Discover financial modeling techniques employed by leading pharmaceutical companies, including Enanta Pharmaceuticals (ENTA).
- Educators: Implement it as a resource for teaching valuation methods in the context of Enanta Pharmaceuticals (ENTA).
What the Template Contains
- Pre-Filled DCF Model: Enanta Pharmaceuticals’ financial data preloaded for immediate use.
- WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
- Financial Ratios: Evaluate Enanta Pharmaceuticals’ profitability, leverage, and efficiency.
- Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
- Financial Statements: Annual and quarterly reports to support detailed analysis.
- Interactive Dashboard: Easily visualize key valuation metrics and results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.